Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: Results of the all-bfm-sct 2003 trial

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages 1275-1284

  Bader, Peter ^a   Kreyenberg, Hermann ^a   Von Stackelberg, Arend ^a   Eckert, Cornelia ^a   Salzmann Manrique, Emilia ^a   Meisel, Roland ^b   Poetschger, Ulrike ^j   Stachel, Daniel ^c   Schrappe, Martin ^d   Alten, Julia ^d   Schrauder, Andre ^d   Schulz, Ansgar ^e   Lang, Peter ^f   Müller, Ingo ^g   Albert, Michael H ^h   Willasch, Andre M ⁱ   Klingebiel, Thomas E ⁱ   Peters, Christina ^j  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j ST ANNA CHILDREN S HOSPITAL   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; MELPHALAN; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL (TOPIC); CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EVENT FREE SURVIVAL; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; WHOLE BODY RADIATION; ADOLESCENT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; AREA UNDER THE CURVE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEWBORN; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; REMISSION; RISK FACTOR; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; ROC CURVE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927131996     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.4631     Document Type: Article

References (64)

1. Gaynon PS, Trigg ME, Heerema NA, et al: Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14: 2223-2233, 2000
2. Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 339:605-615, 1998
3. Schrappe M, Reiter A, Zimmermann M, et al: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995: Berlin-Frankfurt-Munster. Leukemia 14:2205-2222, 2000
4. Hahn T, Wall D, Camitta B, et al: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: An evidence-based review. Biol Blood Marrow Transplant 11:823-861, 2005
5. Borgmann A, von Stackelberg A, Hartmann R, et al: Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 101:3835-3839, 2003
6. Eapen M, Raetz E, Zhang MJ, et al: Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: A collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 107:4961-4967, 2006
7. Eckert C, Biondi A, Seeger K, et al: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358: 1239-1241, 2001
8. Woolfrey AE, Anasetti C, Storer B, et al: Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 99:2002-2008, 2002
9. Eckert C, Henze G, Seeger K, et al: Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 31:2736-2742, 2013
10. Schrauder A, von Stackelberg A, Schrappe M, et al: Allogeneic hematopoietic SCT in children with ALL: Current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 41:S71-S74, 2008 (suppl 2)
11. Knechtli CJ, Goulden NJ, Hancock JP, et al: Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92:4072-4079, 1998
12. van der Velden VH, Joosten SA, Willemse MJ, et al: Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 15: 1485-1487, 2001
13. Uzunel M, Mattsson J, Jaksch M, et al: The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 98:1982-1984, 2001
14. Bader P, Hancock J, Kreyenberg H, et al: Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16:1668-1672, 2002
15. Goulden N, Bader P, Van Der Velden V, et al: Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 122:24-29, 2003
16. van der Velden VH, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21: 604-611, 2007
17. Bader P, Kreyenberg H, Henze GH, et al: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group. J Clin Oncol 27: 377-384, 2009
18. Logan AC, Vashi N, Faham M, et al: Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts posttransplantation relapse and survival. Biol Blood Marrow Transplant 20:1307-1313, 2014
19. Bar M, Wood BL, Radich JP, et al: Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment 2014:421723, 2014
20. Bader P, Klingebiel T, Schaudt A, et al: Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children. Leukemia 13:2079-2086, 1999
21. Bader P, Kreyenberg H, Hoelle W, et al: Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for preemptive immunotherapy? J Clin Oncol 22:1696-1706, 2004
22. Collins RH Jr, Rogers ZR, Bennett M, et al: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 10:391-395, 1992
23. Abraham R, Szer J, Bardy P, et al: Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transplant 20:773-777, 1997
24. Gandemer V, Pochon C, Oger E, et al: Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: The results of the French minimal residual disease-guided protocol. Br J Haematol 165:392-401, 2014
25. Mehta J, Powles R, Singhal S, et al: Cytokinemediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 16:133-137, 1995
26. Kolb HJ, Mittermüller J, Clemm C, et al: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465, 1990
27. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: 2041-2050, 1995
28. Slavin S, Naparstek E, Nagler A, et al: Allogeneic cell therapy: The treatment of choice for all hematologic malignancies relapsing post BMT. Blood 87:4011-4013, 1996
29. Slavin S, Naparstek E, Nagler A, et al: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195-2204, 1996
30. Or R, Ackerstein A, Nagler A, et al: Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. J Immunother 21:447-453, 1998
31. Johnson BD, Truitt RL: Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85:3302-3312, 1995
32. van Rhee F, Lin F, Cullis JO, et al: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377-3383, 1994
33. Pulsipher MA, Bader P, Klingebiel T, et al: Allogeneic transplantation for pediatric acute lymphoblastic leukemia: The emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 15:62-71, 2008
34. Spinelli O, Peruta B, Tosi M, et al: Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 92:612-618, 2007
35. Campana D, Leung W: Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol 162:147-161, 2013
36. Grupp SA, Kalos M, Barrett D, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518, 2013
37. Topp MS, Gökbuget N, Zugmaier G, et al: Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120: 5185-5187, 2012
38. Schlegel P, Lang P, Zugmaier G, et al: Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 99:1212-1219, 2014
39. Kalos M, Nazimuddin F, Finklestein JM, et al: Long-term functional persistence, B cell aplasia and anti-leukemia efficacy in refractory B cell malignancies following T cell immunotherapy using CARredirected T cells targeting CD19. Blood 122:163, 2013 (abstr)
40. van Dongen JJ, Langerak AW, Brüggemann M, et al: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257-2317, 2003
41. Kreyenberg H, Eckert C, Yarkin Y, et al: Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation. Leukemia 23:1355-1358, 2009
42. Pongers-Willemse MJ, Seriu T, Stolz F, et al: Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 CONCERTED ACTION-Investigation of minimal residual disease in acute leukemia. Leukemia 13:110-118, 1999
43. Szczepañski T, Orfão A, van der Velden VH, et al: Minimal residual disease in leukaemia patients. Lancet Oncol 2:409-417, 2001
44. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
45. Freeman GH, Halton JH: Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 38:141-149, 1951
46. Valz PD, Thompson ME: Exact inference for Kendall's S and Spearman's - with extension to Fisher's exact test in r - c contingency tables. J Comput Graph Stat 3:459-472, 1994
47. Blanche P, Dartigues JF, Jacqmin-Gadda H: Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 32:5381-5397, 2013
48. Hung H, Chiang C-T: Estimation methods for time-dependent AUC models with survival data. Can J Stat 38:8-26, 2010
49. Heagerty PJ, Zheng Y: Survival model predictive accuracy and ROC curves. Biometrics 61:92-105, 2005
50. Heagerty PJ, Lumley T, Pepe MS: Timedependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:337-344, 2000
51. The R Foundation for Statistical Computing: R, a Language and Environment for Statistical Computing and Graphics. Vienna, Austria, University of Vienna, 2003
52. Rujkijyanont P, Morris C, Kang G, et al: Riskadapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia. Blood Cancer J 3:e137, 2013
53. Lankester A, Locatelli F, Bader P, et al: Will post transplant cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant [epub ahead of print on July 23, 2014]
54. Knechtli CJ, Goulden NJ, Hancock JP, et al: Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 102:860-871, 1998
55. Pérez-Simón JA, Caballero D, Diez-Campelo M, et al: Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 16:1423-1431, 2002
56. Uzunel M, Jaksch M, Mattsson J, et al: Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Br J Haematol 122:788-794, 2003
57. Zetterquist H, Mattsson J, Uzunel M, et al: Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplant 25:843-851, 2000
58. Bunin N, Johnston DA, Roberts WM, et al: Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features. Br J Haematol 120:711-715, 2003
59. Sánchez J, Serrano J, Gómez P, et al: Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 116:686-694, 2002
60. Miglino M, Berisso G, Grasso R, et al: Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): Predictive role of minimal residual disease monitoring on relapse. Bone Marrow Transplant 30:579-585, 2002
61. Balduzzi A, Di Maio L, Silvestri D, et al: Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: Is there any room for intervention? Br J Haematol 164:396-408, 2014
62. Terwey TH, Hemmati PG, Nagy M, et al: Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant 20:1522-1529, 2014
63. Fronkova E, Muzikova K, Mejstrikova E, et al: B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant 42:187-196, 2008
64. Shah NN, Borowitz MJ, Steinberg SM, et al: Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 20:1033-1039, 2014